SCHEMBL3159479

SCHEMBL3159479

Cc1noc(NS(=O)(=O)c2ccc(C(=O)NCc3ccc(C(F)(F)F)cc3)cc2)c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 1/20 0.67
SCN3A Q9NY46 1/20 0.58
TP53 P04637 2/20 0.58
POLB P06746 1/20 0.54
EDNRA P25101 7/20 0.54
EDNRB P24530 5/20 0.54
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
MAPT P10636 3/20 0.53
LMNA P02545 1/20 0.53
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
CYP2C9 P11712 2/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP3A4 P08684 1/20 0.52
PPARA Q07869 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163135 0.87 SCN3A (0.59) P2RY1SCN3AMEN1KMT2AMAPT
SCHEMBL7849820 0.85 P2RY1 (0.80) P2RY1TP53EDNRAEDNRBMEN1
SCHEMBL3169627 0.83 SCN3A (0.59) SCN3AMEN1KMT2AMAPTLMNA
SCHEMBL3153875 0.82 SCN3A (0.61) SCN3AEDNRAMEN1KMT2AMAPT
SCHEMBL3167830 0.79 SCN3A (0.59) SCN3AMEN1KMT2AMAPTLMNA
SCHEMBL3154182 0.78 SCN3A (0.61) SCN3AMEN1KMT2AMAPTLMNA
SCHEMBL3161312 0.77 SCN3A (0.64) SCN3AMEN1KMT2AMAPTLMNA
SCHEMBL3172289 0.77 SCN3A (0.67) P2RY1SCN3AMEN1KMT2AMAPT
SCHEMBL12010898 0.76 MAPT (0.80) SCN3AMEN1KMT2AMAPTLMNA
SCHEMBL3160236 0.76 SCN3A (0.69) SCN3AMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 P2RY1 143/4885SCN3A 13/4885TP53 4855/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 P2RY1 143/4885SCN3A 13/4885TP53 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.